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Abstract
Background: Disturbances of the fatty acids composition in plasma and red blood cells and eicosanoid synthesis
play an important role in the metabolic syndrome (MS) formation.
Methods: The observation group included 61 people with metabolic syndrome (30 patients with MS and normal
levels of insulin, 31 people with MS and insulin resistance - IR). The parameters of carbohydrate and lipid
metabolism in blood serum were examined. The composition of nonesterified fatty acids (NEFA), fatty acid (FA) of
red blood cells lipids was analyzed by gas-liquid chromatography. Eicosanoids level in MS patients blood serum
was studied by enzyme immunoassay.
Results: In MS patients in the absence of glucose-insulin homeostasis disturbances and in patients with IR the
accumulation of polyunsaturated fatty acids (18:2 n6, 18:3 n3, 22:4 n6) and lower pool of saturated FA (12:0, 14:0,
16: 0, 17:0) in plasma were discovered. A deficit of polyunsaturated FA (18:3 n3, 20:4 n6) with a predominance of
on-saturated FA (14:0, 18:0) in erythrocyte membranes was revealed. In MS patients regardless of the carbohydrate
metabolism status high levels of leukotriene B4 and 6-keto-prostaglandin-F1a in serum were found. The
development of IR in MS patients leads to increased synthesis of thromboxane A2.
Conclusion: The results revealed a disturbance in nonesterified fatty acids of plasma lipids and red blood cells,
eicosanoid synthesis in MS patients. The breach of the plasma and cell membranes fatty acids compositions,
synthesis of vasoactive and proinflammatory eicosanoids is an important pathogenetic part of the MS
development.
Background
Metabolic syndrome (MS), which includes a number of
systemic clinical and biochemical processes (insulin resis-
tance, abdominal obesity, hypertension, dyslipidemia),
attracts the attention of endocrinologists, cardiologists,
general practitioners [1-3]. This is due to the large spread
of this syndrome in the population (20%), and its value in
the development of cardiovascular disease, diabetes mel-
litus type 2 [1,4]. There are several hypotheses of MS,
and the theory of insulin resistance (IR) is main [5,6].
According to some authors the formation of insulin
resistance precedes the deficit of essential polyunsatu-
rated fatty acids (PUFA) in the cells. The one of the rea-
sons may be a disturbances of their active receptor (apo
B/100) transport of lipoproteins [7-9]. Endogenous fatty
acid deficiency in cells leads to changes of phospholipids
fatty acid composition and physicochemical properties of
plasma membrane, lowering their liquid, breaking func-
tioning of the insulin receptor and glucose transport sys-
tems. Logical consequence of receptor transfer of fatty
acid (FA) blockade is a compensatory increase in passive
absorption of nonesterified free FA (FFA) by cells
[10-13]. Cells adaptation to this type of FFA transport
activates lipolysis, enhances insulin secretion exponen-
tiating the hyperinsulinemia (HI) formation [14]. In turn,
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further enhances peripheral IR.
Another negative side of physiologically important
PUFA in the cells membrane pool depletion is the dys-
function of biologically active metabolites synthesis -
oxylipins (eicosanoids: prostaglandins, leukotrienes,
thromboxanes), which are the key regulators of endothe-
lial function, immunocompetent cells, platelets [15]. It’s
proved that the disturbance of the eicosanoids synthesis
and it’s imbalance in the body cause the chronic inflam-
mation, arterial hypertension, coronary heart disease,
atherosclerosis, diabetes mellitus [16,17]. Chain of suc-
cessive violations, starting from the pathology of FA
transport receptor, leading to cellular deficiency of
essential fatty acids and eicosanoid synthesis distur-
bance, creating a vicious circle forming MS. However,
nowaday there is no clear evidence supporting the
pathogenetic role of fatty acids and disturbances of their
transport and eicosanoids synthesis dysfunction in the
metabolic syndrome mechanisms.
Purpose: to study the fatty acid composition in plasma
and red blood cells and the level of oxylipins in MS
patients blood with different glucose-insulin homeosta-
sis, to establish the role of fatty acids and their metabo-
lites in the MS pathogenesis.
Materials and methods
76 people (30 men, 46 women) aged 21 to 69 years partici-
pated in a study with informed consent. Criteria proposed
by the American Heart Association were used for the MS
diagnosis [3]. Depending on the availability of MS compo-
nents and changes in glucose-insulin homeostasis 76 peo-
ple were divided into the following groups: Group 1
(control) consisted of 15 persons without MS components,
Group 2 included 30 MS patients with normal levels of
insulin, the third group comprised 31 persons with diag-
nosed MS and IR.
The study of carbohydrate metabolism includes the
determination of the glucose content in the blood
serum fasting and 2 hours after oral glucose load, insu-
lin levels by immunosorbent method (kits of «DRG -
diagnostics» firm, Germany), calculated HOMA index
(fasting insulin level, mU/ml × level fasting plasma glu-
cose, mmol/l/22.5). The serum lipid spectrum was stu-
died by the content of cholesterol, triglycerides (TG),
high density lipoprotein cholesterol (HDL) in serum
with biochemical analyzer Photometer FM 750 (Ger-
many), using sets of firm “Olvex” (Russia). Results were
expressed in mmol/liter. The concentration of low den-
sity lipoproteins cholesterol (LDL) and very low (VLDL)
density were calculated by the formula: LDL = total cho-
lesterol - (HDL + VLDL), VLDL = TG/2,2, the results
were expressed in mmol/liter [18].
The extraction of lipids from erythrocytes was per-
formed by a modified method of Bligh and Dyer [19].
Gas-liquid chromatography of FA methyl ethers was per-
formed on gas-liquid chromatograph “Shimadzu-9A”
(Japan) with a flame ionization detector. Methyl ethers of
erythrocytes FA lipids were obtained by the method of
Carreau and Dyubak [20] and purified by thin-layer chro-
matography. FA methyl ethers were analyzed by capillary
columns. The Chromaton N-AW-DMCS 0,100-0,125
was used as carrier, 5% Silar-5 CP, FFAP - as the liquid
phase. The evaporation temperature was 245°C. The
separation temperature was 210°C. Helium was the gas-
carrier with linear velocity - 20 cm/sec. The identification
was performed using standard mixtures of FA and the
values of the equivalent chain length [21]. Quantitative
calculations were performed using the standard software
of data processing systems Chromatopak-CR 3A. Results
were expressed in relative % of total FA. The level of
eicosanoids (thromboxane B2, 6-keto-prostaglandin F1a,
leukotriene B4) in the blood was studied by enzyme
immunoassay (kits of Amersham Biosciences firm, UK).
Statistical data processing was performed using the
methods of descriptive statistics: the arithmetic mean,
the standard error of arithmetic mean (M ± m), the cri-
teria for significant differences (t) Student.
Results
Expressed clinical and metabolic changes specific for
this syndrome was revealed in MS patients: increased
body mass index, ratio of waist and hips (W/H),
increased blood pressure, increased in the LDL-C. In
both groups MS patients had increased level of proin-
flammatory cytokine (TNF-a) in blood (Table 1).
Qualitative composition of the NEFA in examined
groups is presented by 31 components of individual
fatty acids with carbon chain lengths from C12 to C24,
as with the even and odd number of carbon atoms, nor-
mal and isostructure, saturated, polyunsaturated and
monoenic. Composition of the main FA in plasma and
FA in red blood cells lipids in MS patients is presented
in Table 2. Analysis of the quantitative composition
NEFA showed that MS patients in group 2 in compare
with the control group had a decrease of individual
saturated FA levels: lauric (12:0), myristic (14:0, p <
0.05), palmitic (16:0 p < 0,01), margarine (17:0, p < 0.05)
(Table 2). Among the isostructure acid of the relative
content of 16:0-i (p < 0,01) was almost 3 times
decreased. Since the relative amounts of saturated fatty
acids is reduced the content of polyunsaturated FA is
increased. Proportion of linoleic (18:2 n6) and a-linole-
nic (18:3 n3) acids increased twofold (p < 0,01), which
was reflected in increased total index n6 FA - Σ n6 FA.
Integrated parameter of changes in the FA variety was
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products of double bonds in each of the FA with its
relative percentage. This parameter was increased (p <
0,05). In the third group (MS and IR patients) vector of
changes in the NEFA composition was comparable with
the same in group 2. The obtained results show that
patients with the absence of glucose-insulin homeostasis
disturbances and patients with severe IR had quite pro-
nounced changes in the NEFA composition, caused by a
violation of the transfer and absorption of the saturated
and polyunsaturated FA in the blood cells [22]. The
consequence of these processes can be deficit of essen-
tial polyunsaturated acids in the cells.
To confirm this assumption red blood cells FA lipids
composition in MS patients has been studied. In the ery-
throcytes FA lipids composition 37 individual fatty acids,
saturated and polyunsaturated monoenic, normal, and
isostructure with chain length from C12 to C22, as with
the even and odd number of carbon atoms (Table 2)
were identified. In the quantitative composition of ery-
throcyte FA lipids in surveyed MS patients significant
changes compared with the control group were revealed.
In MS patients without IR in erythrocytes the proportion
20:0 FA was increased, monoenic (16:1 n7, 17:1) and
polyunsaturated (18:3 n3, 20:4 n6) fatty acids were
reduced. An increase in the relatively level of Mead acid
(20:3 n9) was revealed. Compensatory synthesis of Mead
acid occurs with a deficit of polyunsaturated acids family
n6 and n3 [7]. In the group 3 the accumulation of myris-
tic, stearic and arahidonic (20:0) acids was revealed on
the background of significant reduction in the proportion
of essential linoleic acid (18:2 n6), 18:4 n3, arachidonic
(20:4 n6) and 22:4 n6 polyunsaturated FA, increasing
20:3 n9. In both groups the total parameter set-Σ n6 (p <
0.05) and US (p < 0,01) was reduced.
The results testify the modifications of the free fatty
acids composition in blood plasma and erythrocyte fatty
a c i d si np a t i e n t sw i t hM Sc o m p o n e n t s .T h ec a u s e so f
PUFA accumulation in plasma simultaneously with their
Table 1 Clinical and biochemical characteristics of
patients with metabolic syndrome
Parameters Control group,
n=1 5
2 group (with MS),
n=3 1
BMI 21,97 ± 0,65 ***31,55 ± 1,79
Waist circumference,cm 70,45 ± 1,55 ***95,76 ± 3,98
Hip circumference,cm 98,63 ± 1,88 ***116,07 ± 3,40
Waist-hip ration, a.u. 0,71 ± 0,01 ***0,82 ± 0,01
Systolic arterial pressure, mmHg 105 ± 2 ***142 ± 2
Diastolic arterial pressure, mmHg 65 ± 2 ***88 ± 2
Fasting plasma glucose, mmol/l 4,06 ± 0,31 **5,80 ± 0,22
Glucose after oral load, mmol/l 4,32 ± 0,39 *6,52 ± 0,65
Insulin, mU/ml 8,08 ± 1,04 ***18,50 ± 2,19
HOMA index 1,50 ± 0,21 ***4,50 ± 0,66
TC, mmol/l 4,44 ± 0,21 **5,80 ± 0,29
ТG, mmol/l 0,68 ± 0,07 *1,79 ± 0,14
HDL, mmol/l 1,41 ± 0,11 1,14 ± 0,06
LDL, mmol/l 2,72 ± 0,22 *3,88 ± 0,28
Abbreviation: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared);
Note: tabl. 1, 2, 3 (*) - Statistically significant differences linked to the control
group: * - p < 0.05, ** - p < 0.01, *** - p < 0,001.
Table 2 The content of NEFA in plasma and FA in
erythrocyte lipids in patients with metabolic syndrome
Fatty acids, % Control group,
n=1 5
2 group (with MS),
n=3 1
12:0 0,65 ± 0,10
0,40 ± 0,01
*0,45 ± 0,07
*0,2 ± 0,07
14:0 2,96 ± 0,21
0,65 ± 0,04
2,91 ± 0,17
*0,76 ± 0,02
15:0 0,88 ± 0,11
0,28 ± 0,02
0,78 ± 0,13
0,29 ± 0,01
16:0 33,76 ± 1,25
23,37 ± 0,32
*30,79 ± 1,25
24,03 ± 0,37
16:0-i 1,62 ± 0,35
0,40 ± 0,01
**0,41 ± 0,07
0,50 ± 0,01
16:1n7 2,01 ± 0,27
0,8 ± 0,03
2,17 ± 0,32
**0,64 ± 0,03
17:0 1,25 ± 0,19
0,45 ± 0,04
*0,92 ± 0,03
0,43 ± 0,03
17:1 0,3 ± 0,01
0,37 ± 0,025
0,35 ± 0,08
***0,16 ± 0,02
18:0 31,32 ± 5,07
17,23 ± 0,29
29,15 ± 4,85
***22,8 ± 0,9
18:0-i 0,25 ± 0,08
0,80 ± 0,01
Traces
**0,57 ± 0,07
18:2n6 7,53 ± 1,68
13,74 ± 0,53
*11,13 ± 2,21
*11,98 ± 0,34
18:3n6 0,13 ± 0,03
0,20 ± 0,01
Traces
0,21 ± 0,02
18:3n3 0,51 ± 0,11
0,20 ± 0,01
*0,82 ± 0,17
Traces
20:0 0,89 ± 0,09
0,18 ± 0,02
0,74 ± 0,11
**0,3 ± 0,03
20:3n9 0,60 ± 0,21
0,56 ± 0,24
**0,36 ± 0,06
*0,88 ± 0,18
20:4n6 0,36 ± 0,06
12,13 ± 0,24
0,41 ± 0,06
***10,14 ± 0,35
20:5n3 0,66 ± 0,11
1,08 ± 0,11
0,45 ± 0,07
**1,58 ± 0,11
22:1 Traces
0,25 ± 0,02
Traces
***0,67 ± 0,10
22:4n6 1,74 ± 0,12
2,15 ± 0,11
1,94 ± 0,11
**1,58 ± 0,09
Σ n6 7,77 ± 1,71
30,1 ± 0,6
*11,42 ± 2,27
***25,7 ± 0,67
Σ n3 1,01 ± 0,18
9,98 ± 0,78
1,21 ± 0,22
9,94 ± 0,47
Unsaturation index 38,41 ± 7,30
155,98 ± 1,33
*49,08 ± 8,83
**133,16 ± 6,17
Note: in numerator - the nonesterified FA in plasma, in denominator - FA in
erythrocyte lipids
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receptor apparatus responsible for the active capture of
the FA as part of lipoproteins. Changing of the composi-
tion of fatty acid (FA) in the cells membranes, mainly in
the downward the number of esterified essential polyun-
saturated fatty acids into the phospholipids leads to
decreasing the negative charge of the membrane,
increasing its microviscosity, activation of proinflamma-
tory eicosanoids synthesis and increased sensitivity of
arteries smooth muscle cells to the vasoconstrictors
effects [23,24]. Presented disturbances are the main
pathogenetic factors of cardiovascular disease formation
(hypertension, stroke, myocardial infarction). The
observed decrease of arachidonic acid in red blood cells
indicates on a disturbances in eicosanoids cycle and
increased oxylipins synthesis with expressed vasocon-
strictor (thromboxane A2) and proinflammatory (leuko-
triene B4) properties.
The research of eicosanoids levels in blood serum of MS
patients showed that patients from 2 and 3 groups had
increased concentrations of 6-keto-prostaglandin F1a (p <
0,001) and leukotriene B4 (p < 0.001) in contrast with the
control group (Table 3). In the third group increased level
of thromboxane B2 (p < 0,001) was shown, which was not
noted in the 2 group. Elevated levels of leukotrienes,
which are the strongest mediators of allergic and inflam-
matory processes as well as a high content of TNF-a in
the MS patients blood indicate on the activation of inflam-
matory reactions [25]. The observed excess of 6-keto-pros-
taglandin F1a, which is a potent vasodilator [26] in MS
patients suggests the launch of the compensatory mechan-
isms that support the balance preservation between the
formation of pro-and anti-oxylipins. However, the attempt
of the organism to maintain a dynamic equilibrium
between leukotrienes and prostaglandins has its limita-
tions. Identified disturbances can be a decisive step in the
launch of the mechanisms of cardiovascular diseases, dia-
betes and other pathologies developing in MS patients.
This was confirmed by the overproduction of thrombox-
ane B2 in patients with MS complicated by insulin resis-
tance, which indicates a connection of MS pathogenetic
mechanisms such as vasoconstriction, hypercoagulation,
which are amplifying disturbances in the vascular wall
dysfunction, leading to the increased cells resistance to
insulin [16].
Significant role in the modification of the FA and the
formation of a substrate for the synthesis of eicosanoids
also belongs to the delta-5 and 6-desaturases. However,
in our work activity desaturases has not been studied.
Need for further research into the causes modifications
of the FA in the pathogenesis of MS.
Thus, the development of MS is accompanied by a
modification of nonesterified and esterified FA in
plasma and blood cells. One of the reasons for FA com-
position changes may be a disturbances of their active
transport. This leads to the changes in the cell mem-
branes structure, a decrease of insulin-dependent glu-
cose transporter functional activity, disruption of
oxylipins synthesis and imbalance between pro-and anti-
inflammatory, vasoconstrictor and vasodilatory eicosa-
noids. Displacement of the dynamic equilibrium of the
cytoprotective and cytotoxic eicosanoids biosynthesis in
favor of the latter, the disruption of insulin receptors
initiate the pathogenetic mechanisms of development
and progression of metabolic complications is a major
component of the cardiovascular diseases, diabetes for-
mation. The breach of the fatty acids of plasma and cell
membranes, synthesis of vasoactive and proinflamma-
tory eicosanoids is the cause of MS. These findings
reveal an important role of fatty acids and their metabo-
lites in the pathogenesis of the metabolic syndrome,
which should be considered in the design and choice of
preventive and therapeutic interventions directed to pre-
venting or eliminating the identified irregularities in
lipid-transfer, cyclooxygenase and lipoxygenase systems.
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